Celgene Co. (CELG) Shares Bought by Skandinaviska Enskilda Banken AB publ
Skandinaviska Enskilda Banken AB publ boosted its position in shares of Celgene Co. (NASDAQ:CELG) by 144.8% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 993,229 shares of the biopharmaceutical company’s stock after purchasing an additional 587,500 shares during the quarter. Skandinaviska Enskilda Banken AB publ’s holdings in Celgene were worth $88,884,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Fisher Asset Management LLC lifted its position in shares of Celgene by 4.1% in the second quarter. Fisher Asset Management LLC now owns 322,086 shares of the biopharmaceutical company’s stock valued at $25,580,000 after acquiring an additional 12,743 shares in the last quarter. Xact Kapitalforvaltning AB increased its stake in Celgene by 13.4% in the second quarter. Xact Kapitalforvaltning AB now owns 209,138 shares of the biopharmaceutical company’s stock valued at $16,610,000 after purchasing an additional 24,765 shares during the last quarter. First Citizens Bank & Trust Co. acquired a new position in Celgene in the second quarter valued at $282,000. Daiwa SB Investments Ltd. acquired a new position in Celgene in the second quarter valued at $631,000. Finally, Acropolis Investment Management LLC acquired a new position in Celgene in the second quarter valued at $112,000. Institutional investors own 73.58% of the company’s stock.
Several equities analysts recently commented on CELG shares. Morgan Stanley upped their target price on Celgene from $90.00 to $91.00 and gave the company an “equal weight” rating in a research note on Friday, July 13th. Zacks Investment Research lowered Celgene from a “hold” rating to a “sell” rating in a research note on Wednesday, July 18th. SunTrust Banks reiterated a “hold” rating and issued a $101.00 target price on shares of Celgene in a research note on Friday, July 27th. Mizuho reiterated a “buy” rating and issued a $129.00 target price on shares of Celgene in a research note on Tuesday, July 31st. Finally, BidaskClub upgraded Celgene from a “hold” rating to a “buy” rating in a research note on Thursday, August 16th. Three equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Celgene currently has an average rating of “Buy” and an average target price of $117.91.
Celgene (NASDAQ:CELG) last announced its quarterly earnings results on Thursday, October 25th. The biopharmaceutical company reported $2.29 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.02 by $0.27. The company had revenue of $3.89 billion during the quarter, compared to analyst estimates of $3.83 billion. Celgene had a return on equity of 108.76% and a net margin of 19.64%. Research analysts predict that Celgene Co. will post 7.45 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This report was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://www.thecerbatgem.com/2018/11/10/celgene-co-celg-shares-bought-by-skandinaviska-enskilda-banken-ab-publ.html.
Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.
See Also: How Do I Invest in Dividend Stocks
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.